We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-2.98%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$251M
AUM Growth
-$19M
Cap. Flow
-$2.24M
Cap. Flow %
-0.89%
Top 10 Hldgs %
7.1%
Holding
477
New
43
Increased
256
Reduced
137
Closed
41

Top Buys

Rank Stock Value
1
MOS icon
The Mosaic Company
MOS
+$962K
2
EMB icon
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
+$944K
3
ENPH icon
Enphase Energy
ENPH
+$834K
4
DVN icon
Devon Energy
DVN
+$751K
5
IT icon
Gartner
IT
+$742K

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$785K
2
LHX icon
L3Harris
LHX
+$740K
3
A icon
Agilent Technologies
A
+$713K
4
CPRT icon
Copart
CPRT
+$688K
5
CQP icon
Cheniere Energy
CQP
+$687K

Sector Composition

Rank Sector Weight
1 Healthcare 18.83%
2 Real Estate 17.55%
3 Materials 12.77%
4 Financials 9.88%
5 Energy 9.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
276
Ascendis Pharma A/S
ASND
$16.7B
$299K 0.12%
2,900
+44
+2% +$4.17K
FDUS icon
277
Fidus Investment
FDUS
$766M
$294K 0.12%
17,133
-6,586
-28% -$125K
INSM icon
278
Insmed
INSM
$22.6B
$292K 0.12%
13,541
+197
+1% +$4.72K
SAGE
279
DELISTED
Sage Therapeutics
SAGE
$289K 0.12%
7,388
+107
+1% +$4.14K
VTYX
280
DELISTED
Ventyx Biosciences
VTYX
$280K 0.11%
8,023
+53
+0.7% +$1.17K
BMRN icon
281
BioMarin Pharmaceuticals
BMRN
$12B
$279K 0.11%
3,294
+48
+1% +$4.27K
TBPH icon
282
Theravance Biopharma
TBPH
$875M
$279K 0.11%
27,509
+400
+1% +$3.75K
PRTA icon
283
Prothena Corp
PRTA
$448M
$276K 0.11%
4,557
+34
+0.8% +$1.07K
NBIX icon
284
Neurocrine Biosciences
NBIX
$18.4B
$274K 0.11%
2,582
+38
+1% +$3.86K
LGND icon
285
Ligand Pharmaceuticals
LGND
$5.94B
$271K 0.11%
5,048
+74
+1% +$4.35K
MIRM icon
286
Mirum Pharmaceuticals
MIRM
$6.84B
$259K 0.1%
12,318
+181
+1% +$4.36K
EFL
287
DELISTED
Eaton Vance Floating-Rate 2022 Target Term Trust Common Shares of Beneficial Interest
EFL
$257K 0.1%
+29,829
New +$256K
CTIC
288
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$252K 0.1%
43,370
+635
+1% +$3.96K
GILD icon
289
Gilead Sciences
GILD
$167B
$251K 0.1%
4,074
+59
+1% +$3.72K
MCRB icon
290
Seres Therapeutics
MCRB
$46.5M
$248K 0.1%
1,935
+15
+0.8% +$1.54K
TVTX icon
291
Travere Therapeutics
TVTX
$5.2B
$247K 0.1%
10,019
+144
+1% +$3.72K
RXDX
292
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$247K 0.1%
4,184
+32
+0.8% +$1.46K
VNDA icon
293
Vanda Pharmaceuticals
VNDA
$310M
$246K 0.1%
24,934
+365
+1% +$3.85K
GAIN icon
294
Gladstone Investment Corp
GAIN
$655M
$243K 0.1%
20,081
-4,584
-19% -$65.9K
ONC
295
BeOne Medicines Ltd
ONC
$34.3B
$240K 0.1%
1,781
+23
+1% +$3.95K
ACAD icon
296
Acadia Pharmaceuticals
ACAD
$4.45B
$237K 0.09%
14,493
+213
+1% +$3.45K
MRSN
297
DELISTED
Mersana Therapeutics
MRSN
$237K 0.09%
1,402
+10
+0.7% +$1.63K
BNTX icon
298
BioNTech
BNTX
$23.4B
$236K 0.09%
1,747
+26
+2% +$3.98K
BTX
299
BlackRock Technology and Private Equity Term Trust
BTX
$919M
$236K 0.09%
32,478
-3,909
-11% -$32.7K
KRTX
300
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$236K 0.09%
1,050
+2
+0.2% +$405
10 11
12
13 14

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2022 Portfolio in Review

As of Q3 2022, Virtus ETF Advisers held 477 positions worth $251M, down 7% from $270M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus ETF Advisers's Q3 2022 filing shows 43 new, 256 increased, 137 reduced and 41 closed positions. Its largest new stake was iShares JPMorgan USD Emerging Markets Bond ETF: 11,040 shares worth $877K. The largest sale was Moderna, an estimated $785K.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 17% a quarter earlier, followed by Real Estate and Materials.

  • Virtus ETF Advisers's largest Q3 2022 buy was iShares JPMorgan USD Emerging Markets Bond ETF: 11,040 shares worth $877K.
  • Virtus ETF Advisers added most to The Mosaic Company in Q3 2022, an estimated $962K increase.
  • Virtus ETF Advisers's biggest Q3 2022 reduction was Moderna, cutting an estimated $785K.
  • Virtus ETF Advisers fully exited L3Harris in Q3 2022, selling an estimated $740K.
  • Virtus ETF Advisers's ten largest holdings make up 7.1% of its $251M portfolio in Q3 2022.
  • Virtus ETF Advisers opened 43 new positions and closed 41 in Q3 2022.
  • Virtus ETF Advisers's portfolio value fell 7% quarter-over-quarter to $251M.

Based on Virtus ETF Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.